Animal health company Zoetis (NYSE: ZTS) fell short of the market’s revenue expectations in Q1 CY2026 as sales rose 2.9% year on year to $2.26 billion. The company’s full-year revenue guidance of $9.82 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $1.53 per share was 5.3% below analysts’ consensus estimates.
Is now the time to buy ZTS? Find out in our full research report (it’s free for active Edge members).
Zoetis (ZTS) Q1 CY2026 Highlights:
- Revenue: $2.26 billion vs analyst estimates of $2.31 billion (2.9% year-on-year growth, 2.1% miss)
- Adjusted EPS: $1.53 vs analyst expectations of $1.62 (5.3% miss)
- Adjusted EBITDA: $1.02 billion vs analyst estimates of $1.05 billion (45% margin, 2.7% miss)
- The company dropped its revenue guidance for the full year to $9.82 billion at the midpoint from $9.93 billion, a 1.1% decrease
- Management lowered its full-year Adjusted EPS guidance to $6.93 at the midpoint, a 1.8% decrease
- Operating Margin: 35.4%, down from 38.5% in the same quarter last year
- Market Capitalization: $36.72 billion
StockStory’s Take
Zoetis faced a challenging first quarter of 2026 as its results missed Wall Street’s expectations, prompting a significant negative reaction from investors. Management attributed the underperformance to a convergence of factors, including increased price sensitivity among pet owners, lower veterinary clinic traffic, and intensified competition in key pet care categories. CEO Kristin Peck noted that “the quarter unfolded differently than expected, particularly in companion animal,” emphasizing that aggressive pricing and new market entrants compressed growth, especially in dermatology and parasiticide franchises. The company also highlighted that unfavorable weather, such as winter storms, further reduced clinic visits, compounding these headwinds.
Looking ahead, Zoetis’ revised guidance reflects persistent headwinds in the companion animal segment and continued competitive pressure. Management stated that the company is prioritizing commercial execution and cost discipline to adapt to the tougher environment. CFO Wetteny Joseph explained, “We are taking decisive action to sharpen commercial execution and drive cost discipline.” Zoetis is focusing on targeted affordability programs, launching new loyalty options at the point of sale, and advancing a pipeline of potential blockbuster products. Leadership believes that portfolio optimization and execution, particularly in new product launches, will be critical for stabilizing results before the next wave of innovation-driven growth expected in the coming years.
Key Insights from Management’s Remarks
Management pointed to a mix of macroeconomic and competitive forces shaping Q1 results, with particular weakness in U.S. companion animal, while livestock and diagnostics showed resilience. Several strategic actions were identified to address these pressures and support long-term growth.
- Companion animal segment headwinds: Softer demand for premium pet care products was driven by price sensitivity among pet owners and lower veterinary clinic traffic. Zoetis’ leading dermatology and parasiticide franchises, such as Apoquel and Simparica, were most impacted, with increased competition and aggressive pricing from branded rivals. Generic competitors affected older blockbusters like Convenia and Cerenia but did not play a significant role in the main innovative franchises.
- Intensified competitive environment: The quarter saw a surge in new entrants and heightened promotional activity, particularly in dermatology and parasiticides, which did not translate into overall market expansion. CEO Kristin Peck emphasized, “What was different in Q1 was the pace and level of activity, more entrants across more markets with competitors leaning more heavily and aggressive pricing and incentives.”
- Shift in consumer behavior: Pet owners delayed routine veterinary visits and extended dosing schedules, opting for more affordable options. Management responded by introducing targeted point-of-sale loyalty and affordability programs designed to address immediate economic challenges faced by pet owners.
- Diagnostics and livestock as relative bright spots: While companion animal sales lagged, Zoetis reported strong international growth and solid performance in diagnostics and livestock, with the latter benefiting from robust demand for protein and disease-driven vaccine adoption. The company’s bios portfolio, especially in cattle and poultry, supported this momentum.
- Cost and productivity initiatives: In response to the revenue shortfall, Zoetis launched a comprehensive cost and productivity program to tighten discretionary spending, improve procurement, and drive operating efficiencies. Management is also accelerating the commercialization of new products, such as long-acting monoclonal antibodies, and expanding into new categories through targeted acquisitions like Neogen’s animal genomics business.
Drivers of Future Performance
Management expects ongoing macroeconomic and competitive pressures to shape performance for the remainder of the year, with stabilization efforts centered on commercial execution and strategic product launches.
- Commercial execution and affordability: Zoetis is intensifying efforts to engage veterinarians with integrated solutions and to address pet owner price sensitivity through targeted loyalty programs and simpler point-of-sale options. The company is not planning broad price cuts but is refining promotional strategies and affordability initiatives to drive prescription volume and support clinic economics.
- Innovation pipeline and product launches: The company is advancing convenience-led lifecycle innovations, such as long-acting monoclonal antibodies and new product approvals like Convenia RTU in Canada. Management expects these launches, along with a pipeline of 12 potential blockbusters, to contribute meaningfully to growth in late 2027 and beyond, but near-term impact will be limited.
- Portfolio mix and international growth: Livestock and diagnostics are expected to offset some companion animal weakness, with livestock benefiting from favorable market conditions and protein demand. International growth, especially in emerging markets where standards of care are maturing, remains a focus, though developed markets continue to face similar pressures as the U.S.
Catalysts in Upcoming Quarters
In upcoming quarters, the StockStory team will be watching (1) whether Zoetis can stabilize U.S. companion animal sales through targeted affordability and loyalty initiatives, (2) the trajectory of new product launches, particularly long-acting monoclonal antibodies and the integration of Neogen’s genomics business, and (3) continued momentum in livestock and diagnostics. Progress on cost discipline and portfolio optimization will also be critical for gauging execution.
Zoetis currently trades at $87.59, down from $111.22 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).
High Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
